摘要目的:探讨点阵激光联合卤米松乳膏透皮给药治疗增生性瘢痕的有效性及安全性。方法:2014年1月至2019年12月，安徽医科大学第二附属医院皮肤性病科门诊增生性瘢痕患者123例。观察组63例，男30例，女33例；年龄7～69(31.7±14.6)岁；给予卤米松乳膏外用，早晚各1次，联合点阵激光透皮给药，每周1次，疗程3个月。对照组60例，男28例，女32例；年龄10～71(32.8±15.1)岁；给予卤米松乳膏外用，早晚各1次，疗程3个月。结果:123例患者均完成临床试验。观察组有效率66.7%(42/63例)，其中痊愈18例，显效18例；有效6例，无效21例；对照组有效率20.0%(12/60例)，其中痊愈0例，显效7例，有效5例，无效48例。观察组有效率明显优于对照组( P<0.05)，观察组无不良反应。 结论:点阵激光透皮给药联合卤米松乳膏外用治疗增生性瘢痕疗效明显、安全。

abstractsObjective:To investigate the safety and effectiveness of dot matrix laser combined with transdermal administration in the treatment of hypertrophic scars.Methods:From January 2014 to December 2019, 123 patients with hypertrophic scars in the Dermatology Clinic, the Second Affiliated Hospital of Anhui Medical University. Observation group included 63 cases, 30 males and 33 females, aged 7 to 69 (31.7±14.6) years; given lomatasone cream for topical application, once in the morning and evening, combined with lattice laser transdermal administration, once a week for 3 months. There were 60 patients in the control group, 28 males and 32 females, aged 10-71 (32.8±15.1) years; topical lomidasone cream was given, one morning and one evening, with a course of 3 months.Results:Clinical trials were completed in 123 patients. The total effective rate in the observation group was 66.7% (42/63), of which 18 cases were cured, and 18 cases were markedly effective; 6 cases were effective, 21 cases were ineffective; the total effective rate in the control group was 20.0% (12/60), of which 0 cases were cured, and the effect was 7 Cases, and 5 cases were effective, 48 cases were ineffective. The effective rate of the observation group was significantly better than that of the control group ( P<0.05), and there were no adverse reactions in the observation group. Conclusions:Lattice laser transdermal administration combined with halomethasone cream for topical treatment of hypertrophic scars is effective, safe, and worthy of clinical application.